Sofinnova Ventures targets $425 mln for Fund IX
Sofinnova Ventures, which targets primarily investments in late-stage clinical drug development companies, is back in market targeting $425 million for Fund IX.
3 July 2014•1 min read
Sofinnova Ventures, which targets primarily investments in late-stage clinical drug development companies, is back in market targeting $425 million for Fund IX.
